Tag: TLX
FDA grants Telix breakthrough therapy designation for renal cancer imaging product
Clinical-stage biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has received confirmation from the FDA that its kidney cancer imaging product TLX250-CDx had been granted breakthrough therapy...
Telix Pharmaceuticals to begin phase two prostate cancer imaging study
Biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has been given the green light to commence a phase two study involving its medical imaging technology on prostate cancer patients.
The com...
Telix Pharmaceuticals partners with Mexican nuclear science firm to advance prostate imaging technology
Australian biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has completed an in-licensing agremeent with Mexico’s Instituto Nacional de Investigaciones Nucleares (ININ) for a clinical-stage ...
Telix Pharmaceuticals acquires Belgium-based Advanced Nuclear Medicine Ingredients
Telix Pharmaceuticals (ASX: TLX) has made a play for Belgium company Advanced Nuclear Medicine Ingredients, with the takeover valuing ANMI at over £5.15 million ($8.07 million).
Under the acquisiti...
Telix Pharmaceuticals readies recruitment for phase 3 trial in renal cancer
Melbourne-based biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) is preparing to commence recruitment for its zirconium imaging in renal cancer oncology (ZIRCON) phase 3 trial for imaging of...
Telix Pharmaceuticals strikes cancer treatment access deal with GenesisCare
Biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has teamed up with the largest private provider of oncology services in Australia and Europe, GenesisCare, to accelerate access to new treatm...
